ATE258560T1 - Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden - Google Patents

Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden

Info

Publication number
ATE258560T1
ATE258560T1 AT97906403T AT97906403T ATE258560T1 AT E258560 T1 ATE258560 T1 AT E258560T1 AT 97906403 T AT97906403 T AT 97906403T AT 97906403 T AT97906403 T AT 97906403T AT E258560 T1 ATE258560 T1 AT E258560T1
Authority
AT
Austria
Prior art keywords
mcp
receptor
antibodies
ccr2
monocyte
Prior art date
Application number
AT97906403T
Other languages
English (en)
Inventor
Peter Lind
Alonso Carlos Martinez
Garcia Jose Mario Mellado
Frade Jose Miguel Rodriguez
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE258560T1 publication Critical patent/ATE258560T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
AT97906403T 1996-03-01 1997-02-27 Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden ATE258560T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600820A SE9600820D0 (sv) 1996-03-01 1996-03-01 Antibodies and their use
PCT/SE1997/000342 WO1997031949A1 (en) 1996-03-01 1997-02-27 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2)

Publications (1)

Publication Number Publication Date
ATE258560T1 true ATE258560T1 (de) 2004-02-15

Family

ID=20401642

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906403T ATE258560T1 (de) 1996-03-01 1997-02-27 Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden

Country Status (11)

Country Link
US (1) US6084075A (de)
EP (1) EP0914345B1 (de)
JP (1) JP2000510685A (de)
AT (1) ATE258560T1 (de)
AU (1) AU724037B2 (de)
DE (1) DE69727382T2 (de)
DK (1) DK0914345T3 (de)
ES (1) ES2210496T3 (de)
PT (1) PT914345E (de)
SE (1) SE9600820D0 (de)
WO (1) WO1997031949A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740701B1 (de) 1994-01-13 2006-12-06 The Regents of the University of California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
US20020019026A1 (en) * 1995-06-05 2002-02-14 Daniel R. Soppet Human g-protein receptor hgber32
GB9705521D0 (en) 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
JP2001514886A (ja) * 1997-08-14 2001-09-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｃｒ２遺伝子のミスセンス対立遺伝子によるａｉｄｓへの進行の遅延
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1783227A1 (de) * 2000-02-03 2007-05-09 Millennium Pharmaceuticals, Inc. Humanisierte Antikörper gegen CCR2 und Verfahren zur deren Verwendung
AU2004208716B2 (en) * 2000-02-03 2007-01-04 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
MXPA02007449A (es) * 2000-02-03 2003-04-14 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y metodos para el uso de los mismos.
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
WO2002072141A2 (en) * 2001-03-09 2002-09-19 William Herman Targeted ligands
DE60216606T2 (de) * 2001-06-07 2007-04-05 Chemocentryx Inc., Mountain View Zellwanderungsassay
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DK1461300T3 (da) 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20050142539A1 (en) * 2002-01-14 2005-06-30 William Herman Targeted ligands
AU2002316574B2 (en) * 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
WO2004050836A2 (en) 2002-11-27 2004-06-17 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
CN1747929B (zh) * 2002-12-20 2010-04-28 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
US20050148507A1 (en) * 2003-05-02 2005-07-07 Boehringer Ingelheim International Gmbh Method for the production of an N-terminally modified chemotactic factor
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
WO2005108431A1 (en) * 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
MX2007010484A (es) * 2005-04-15 2007-10-15 Rappaport Family Inst For Res Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
ES2434852T3 (es) * 2005-04-21 2013-12-17 Chemocentryx, Inc. Anticuerpos que se unen a CCX-CKR2
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (en) * 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
US8710191B2 (en) * 2008-08-18 2014-04-29 Pfizer Inc. Antibodies to CCR2
WO2014064192A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
US11846629B2 (en) 2016-09-20 2023-12-19 Tulane University MonoMac-1 cells expressing CD16 and CD163
JP6824689B2 (ja) * 2016-10-27 2021-02-03 株式会社ナリス化粧品 真皮シミ予防・改善剤及び／又はマクロファージ誘引剤のスクリーニング方法
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4240488A1 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antikörper-wirkstoff-konjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0669979T3 (da) * 1992-11-10 2006-03-06 Genentech Inc C-C CKR-1, kemokinreceptor
US5652133A (en) * 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
EP0740701B1 (de) * 1994-01-13 2006-12-06 The Regents of the University of California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
DE19503303A1 (de) * 1995-02-02 1996-08-08 Teves Gmbh Alfred Filtersystem mit selbsttätigem Filterwechsel für Kraftfahrzeuge

Also Published As

Publication number Publication date
EP0914345A1 (de) 1999-05-12
WO1997031949A1 (en) 1997-09-04
DE69727382D1 (de) 2004-03-04
SE9600820D0 (sv) 1996-03-01
PT914345E (pt) 2004-05-31
AU724037B2 (en) 2000-09-07
DK0914345T3 (da) 2004-05-10
DE69727382T2 (de) 2004-11-04
ES2210496T3 (es) 2004-07-01
EP0914345B1 (de) 2004-01-28
US6084075A (en) 2000-07-04
JP2000510685A (ja) 2000-08-22
AU2110497A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
ATE258560T1 (de) Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden
EP0740701A4 (de) Rezeptoren für das monocyte chemoattractant protein aus säugetieren
ATE150977T1 (de) Markiertes monocyte-chemoattractant- proteinmaterial und medizinische anwendung
WO2000078813A3 (en) Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
DE69736976D1 (de) Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
ATE214943T1 (de) Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor
JP2016106137A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69735367D1 (de) THERAPEUTISCHE MULTISPEZIFISCHE VERBINDUNGEN, DIE ANTIKÖRPER GEGEN DEN FCalpha-REZEPTOR ENTHALTEN
PL336635A1 (en) Proteins of human tool-like receptor and their associated reagents and methods
EE05212B1 (et) Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
DE3750389D1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
EP1908837A3 (de) Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
WO1995019435A3 (en) T cell antigen receptor v region proteins and methods of preparation thereof
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
Kondo et al. Muscarinic cholinergic receptor subtypes in human detrusor muscle studied by labeled and nonlabeled pirenzepine, AFDX-116 and 4DAMP
AU9363398A (en) Hepatitis c receptor protein cd81
DE69728897D1 (de) Saeugetierchemokine
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
ATE235054T1 (de) Elisa testsystem zur bestimmung von substanzen, die die bindung zwischen ig e und dessen receptor inhibiert

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914345

Country of ref document: EP

REN Ceased due to non-payment of the annual fee